Neumora plummets as phase 3 navacaprant data misses key goal
Source: SeekingAlpha
2026-06-15 10:55:07 ET
More on Neumora Therapeutics
- Neumora Therapeutics: Downgrading After Navacaprant Development Setback
- Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
- Neumora Therapeutics GAAP EPS of -$0.30
- Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02
- Seeking Alpha’s Quant Rating on Neumora Therapeutics
Read the full article on Seeking Alpha
For further details see:
Neumora plummets as phase 3 navacaprant data misses key goal
Neumora Therapeutics Inc.
NASDAQ: NMRA
NMRA Trading
0.48% G/L:
$1.629 Last:
324,798 Volume:
$1.60 Open:
NMRA Latest News
June 17, 2026 09:07:00 am
NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations
June 16, 2026 04:44:00 pm
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)
June 15, 2026 08:00:00 am
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
May 12, 2026 04:05:00 pm
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
$499,596,451
52,800,160
10.86%
30
N/A
Biotechnology & Life Sciences
Healthcare
US
Watertown
